PMID- 29390508
OWN - NLM
STAT- MEDLINE
DCOM- 20180220
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 51
DP  - 2017 Dec
TI  - Analysis of early death in newly diagnosed acute promyelocytic leukemia patients.
PG  - e9324
LID - 10.1097/MD.0000000000009324 [doi]
LID - e9324
AB  - The aim of this study was to identify risk factors for early death (ED) in acute 
      promyelocitic leukemia (APL) patients.Clinical records of 49 APL patients who 
      suffered ED were divided into 4 groups: death before treatment or within the 
      first 3 days (immediate death; iED group), death during treatment at least 3 days 
      after commencement (ED after treatment), low/intermediate risk, and high-risk 
      groups.White blood cell (WBC) count, high-risk cases, prothrombin time (PT) 
      prolongation, international society on thrombosis and hemostasis (ISTH) scores 
      (P < .05), bleeding (P = .05), and death due to severe hemorrhage (P = .010) were 
      higher in iED group than ED after treatment. And the time from onset to initial 
      hospitalization or death was significantly shorter (P < .05) in iED patients. LDH 
      level (P = .002), PT prolongation (P = .014), and incidence of grades 3 or 4 
      bleeding (P = .049) were higher in high-risk group than in ED and 
      low/intermediate-risk groups, while the times from onset to the initial 
      hospitalization or death were lower for ED patients in high-risk group 
      (P = .037).We found that different types of EDs have different clinical features. 
      A high WBC count contributes to the occurrence of more ED, which is usually not 
      associated with delay of diagnosis and hospitalization. Current therapeutic 
      strategies to reduce the incidence of ED in these cases are not adequate and will 
      benefit from focused research attention.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights 
      reserved.
FAU - Xu, Fang
AU  - Xu F
AD  - Hematology Department, Nanfang Hospital, Southern Medical University, Guangzhou 
      Hematology Department, Mianyang Central Hospital, Mianyang, China.
FAU - Wang, Chunli
AU  - Wang C
FAU - Yin, Changxin
AU  - Yin C
FAU - Jiang, Xuejie
AU  - Jiang X
FAU - Jiang, Ling
AU  - Jiang L
FAU - Wang, Zhixiang
AU  - Wang Z
FAU - Meng, Fanyi
AU  - Meng F
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Hemoglobins)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - China/epidemiology
MH  - Female
MH  - Hemoglobins/analysis
MH  - Hemorrhage/mortality
MH  - Humans
MH  - L-Lactate Dehydrogenase/blood
MH  - Leukemia, Promyelocytic, Acute/blood/*mortality
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Prothrombin Time
MH  - Time Factors
MH  - Young Adult
PMC - PMC5758210
COIS- All authors have declared no conflicts of interest.
EDAT- 2018/02/03 06:00
MHDA- 2018/02/21 06:00
PMCR- 2017/12/22
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/21 06:00 [medline]
PHST- 2017/12/22 00:00 [pmc-release]
AID - 00005792-201712220-00095 [pii]
AID - MD-D-17-01876 [pii]
AID - 10.1097/MD.0000000000009324 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(51):e9324. doi: 10.1097/MD.0000000000009324.